Eribulin extends overall survival for patients with advanced liposarcoma and leiomyosarcoma

Bookmark and Share
Published: 30 May 2015
Views: 2731
Dr Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium

Dr Schöffski presents, at a press conference at ASCO 2015, findings from a randomised phase III trial point to a promising new therapy for patients with advanced intermediate or high grade liposarcoma or leiomyosarcoma whose disease worsened after two or more lines of initial therapies.

Read the news article for more.